Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DF1001 in Advanced Solid Tumors
2023-503291-24-00Phase 2Completed
- Sponsor
- Dragonfly Therapeutics
- Start
- Nov 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of DF1001 in Nonhematologic neoplasms (4 arms), sponsored by Dragonfly Therapeutics. Primary endpoints: Dose escalation: dose-limiting toxicities, Dose escalation: safety and tolerability and 4 more. Started Nov 2024; status: completed.
02
Drugs
DF1001
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-503291-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503291-24-00.